Abstract & Details
Description
Award ID: 2036463
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improved reliability for coronavirus detection. The proposed project will develop a tissue purification technology to extract (purify) virus from patient samples. Purer samples (more coronavirus, less confounding materials) is anticipated to improve signal from virus and reduce signal from non-virus materials, and is therefore anticipated to improve the reliability of testing (fewer false positives and false negatives). This can potentially impact the social distancing of the pandemic. This Small Business Innovation Research (SBIR) Phase I project of a system to extract purified samples for coronavirus testing for downstream testing, such as PCR-based analysis. The system is a novel purification technology that uses biological (antibodies) and other physical to quickly and reliably extract target microorganisms (here COVID viruses) from human samples. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Henry Ahn
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improved reliability for coronavirus detection. The proposed project will develop a tissue purification technology to extract (purify) virus from patient samples. Purer samples (more coronavirus, less confounding materials) is anticipated to improve signal from virus and reduce signal from non-virus materials, and is therefore anticipated to improve the reliability of testing (fewer false positives and false negatives). This can potentially impact the social distancing of the pandemic. This Small Business Innovation Research (SBIR) Phase I project of a system to extract purified samples for coronavirus testing for downstream testing, such as PCR-based analysis. The system is a novel purification technology that uses biological (antibodies) and other physical to quickly and reliably extract target microorganisms (here COVID viruses) from human samples. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
NSF Program Director: Henry Ahn
| Status | Closed |
|---|---|
| Effective start/end date | 12/15/20 → 03/31/22 |
Funding
- SBIR Phase I: $256,000.00
Active Fiscal Year
- FY2022
Start Fiscal Year
- FY2021
TIP Programs
- SBIR Phase I
Small Business
- Yes
Key Technology Areas
- Biotechnology
- (confidence score: 100%)
- Disaster Prevention and Mitigation
- (confidence score: 100%)
Technology Foci
- Synthetic Biology
- (confidence score: 99%)
- Biotechnology - Other than SynBio
- (confidence score: 80%)
- Pandemic prevention and response
- (confidence score: 100%)
Congressional District at Award
- District n. 03 of Maryland
Current Congressional District
- District n. 03 of Maryland
United States
- Maryland
Core Based Statistical Area (CBSA)
- Baltimore-Columbia-Towson, MD
County
- County: Anne Arundel, MD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint. Learn more about Elsevier's Fingerprint Engine here: https://beta.elsevier.com/products/elsevier-fingerprint-engine